The estimated Net Worth of Yoram Palti is at least $33.7 Million dollars as of 28 August 2018. Prof Palti owns over 4,334 units of NovoCure Ltd stock worth over $17,937,360 and over the last 9 years he sold NVCR stock worth over $15,749,126.
Prof has made over 36 trades of the NovoCure Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 4,334 units of NVCR stock worth $174,530 on 28 August 2018.
The largest trade he's ever made was exercising 147,825 units of NovoCure Ltd stock on 18 April 2016 worth over $25,130. On average, Prof trades about 27,460 units every 23 days since 2015. As of 28 August 2018 he still owns at least 1,041,054 units of NovoCure Ltd stock.
You can see the complete history of Prof Palti stock trades at the bottom of the page.
Prof. Yoram Palti is the Founder & CTO at NovoCure Ltd.
Prof Palti is 83, he's been the Founder & CTO of NovoCure Ltd since . There are no older and 23 younger executives at NovoCure Ltd.
Yoram's mailing address filed with the SEC is C/O NOVOCURE INC., 20 VALLEY STREAM PKWY, SUITE 300, MALVERN, PA, 19355.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ..., and Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: